Scholar Rock Holding Corporation’s SRRK share price has dipped by 12.38%, which has investors questioning if this is right ...

CAMBRIDGE, Mass., March 25, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic ...

Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Scholar Rock believes that its highly selective targeting of pro- and latent forms of myostatin with apitegromab may lead to a clinically meaningful improvement in motor function in patients with SMA.

Also Read: Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth The topline data released in October 2024 showed the study achieved its primary ...

Shares of Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) have earned an average rating of “Buy” from the seven brokerages that are covering the company, MarketBeat reports.

(RTTNews) - Scholar Rock (SRRK) announced the FDA has accepted its Biologics License Application for apitegromab, an investigational muscle-targeted treatment that is being developed to provide ...

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein ...

By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients.